Ovid and Take­da cre­ate a one-team strat­e­gy to steer a neu­ro drug to the world

Je­re­my Levin’s team at Ovid Ther­a­peu­tics has been scour­ing the globe for new drugs to treat or­phan brain dis­eases. And af­ter spend­ing a year in dis­cus­sions with a fast-chang­ing Take­da, the lit­tle biotech and large phar­ma or­ga­ni­za­tion are bond­ing on a tight­ly knit part­ner­ship aimed at joint­ly ad­vanc­ing an ear­ly-stage pro­gram for rare epilep­tic en­cephalopathies that will see Ovid build a new group op­er­a­tion in Cam­bridge, MA.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER